NurExone Appoints Dr. Reuter Investor Relations in Europe
September 28, 2023 08:30 ET
|
NurExone Biologic Inc
NurExone partners with Dr. Reuter Investor Relations for European investor relations services. TSX approves NurExone's warrant amendments.
NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug
September 13, 2023 08:30 ET
|
NurExone Biologic Inc
The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines and large-scale animal studies will not be required. The completed Pre-IND meeting with the...
NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M
September 06, 2023 08:30 ET
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing...
NurExone Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 28, 2023 08:30 ET
|
NurExone Biologic Inc
Completed the first tranche of a non-brokered private placement offering of units for gross proceeds of approximately CAD$1.3 million to extend cash runway into 2024Strengthened the Board of Directors...
NurExone Announces Private Placement
August 09, 2023 08:00 ET
|
NurExone Biologic Inc
Not for distribution to United States newswire services or for dissemination in the United States TORONTO and TEL AVIV, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV:...
NurExone Biologic Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery
July 20, 2023 08:15 ET
|
NurExone Biologic Inc
TORONTO and TEL AVIV, Israel, July 20, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in...
Regeneration and Reinnervation of Spinal Cord in Rats Treated with NurExone's Intranasal ExoPTEN
June 22, 2023 08:00 ET
|
NurExone Biologic Inc
TORONTO and TEL AVIV, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) (FSE: J90) (NRX.V), is pleased to report positive imaging results...
NurExone and Particle Metrix Announce Collaboration in Extracellular Vesicles Analysis Using State-of-the-art Analytic Device
June 01, 2023 08:00 ET
|
NurExone Biologic Inc
MUNICH, Germany and TEL AVIV, Israel, June 01, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing...
NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 24, 2023 07:19 ET
|
NurExone Biologic Inc
TORONTO and TEL AVIV, Israel, May 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing...
NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN, Designed for Treating Acute Spinal Cord Injuries
May 16, 2023 08:30 ET
|
NurExone Biologic Inc
TORONTO and TEL AVIV, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing...